問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Family Medicine

更新時間:2023-09-19

陳宗伯
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

10Cases

2026-08-01 - 2028-12-31

Phase III

Not yet recruiting
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射液

Participate Sites
11Sites

Not yet recruiting1Sites

2024-10-01 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-30 - 2026-05-29

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-11-21 - 2023-12-20

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2023-09-01 - 2026-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2023-09-15 - 2025-10-22

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2024-11-05 - 2027-02-02

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2022-11-01 - 2027-02-22

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2023-09-15 - 2025-10-22

Phase III

Completed
Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight and obesity (STEP 12)
  • Condition/Disease

    overweight and obesity

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2022-10-05 - 2024-02-12

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites